Clinical Site Services International (CSSi), the leader in global patient enrollment solutions for the clinical research industry, is pleased to announce their new partnership with TruBios.
Clinical Site Services International (CSSi), the leader in global patient enrollment solutions for the clinical research industry, is pleased to announce their new partnership with TruBios. TruBios, based out of Rockville, MD, is the only fully integrated US-based biotechnology services company focused on the Latin American region offering customized clinical research, commercialization, and venture capital solutions. TruBios is also an independent corporate partner of Johns Hopkins University MCC.
Clinical Site Services International (CSSi), a division of CSS, is partnering with TruBios to deliver CROs/Pharma and Biotech clients solutions that are focused on site performance while also allowing CSSi to expand its site network in Latin America. Pharmaceutical/CRO clients will be provided with top sites and the expertise and understanding of patients who are willing to participate in clinical research.
"Continuing to deliver the most innovative and proven enrollment solutions for our clients, whether in the US or abroad, is a challenge we embrace and one that our partnership with TruBios will address as we expand our site network in Latin America," said Chris Trizna, President of CSS. "Working together, CSSi and TruBios will be able to offer insight and knowledge to help sites in Latin America identify potential patients by utilizing enrollment strategies that are appropriate to the sites and local communities."
"Clinical Site Services and TruBios represent an impressive collaboration, as both of our companies are committed to providing innovative solutions to accelerate the development of clinical trials," said Dr. Roberto Trujillo, CEO of TruBios. "The TruBios Research Network (TRN) covers approx. 60% of the countries in Latin America and partnering with CSSi to deliver customized enrollment services will only allow both our companies to grow and expand further in those countries."
CSSi delivers high-performing, qualified sites to CRO and Pharma clients through their proprietary site management solutions. CSS has long recognized that only sites are able to enroll patients but sometimes sites are not able to identify patients from within their own databases. Understanding and recognizing this challenge by developing an individualized recruitment plan for each site, prevents delays in enrollment. By partnering with TruBios, CSSi's Latin America clients will have the ability to use qualified sites that are already identified as high performing research facilities.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.